Search hospitals > Quebec > SHERBROOKE
Centre Hospitalier Universitaire de Sherbrooke
Claim this profileSHERBROOKE, Quebec J1H 5N4
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Lymphoma
Conducts research for Non-Hodgkin's Lymphoma
Conducts research for Obesity
134 reported clinical trials
17 medical researchers
Summary
Centre Hospitalier Universitaire de Sherbrooke is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Cancer, Breast Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Obesity and other specialties. Centre Hospitalier Universitaire de Sherbrooke is involved with conducting 134 clinical trials across 249 conditions. There are 17 research doctors associated with this hospital, such as Paul Bessette, MD, Francois Lamontagne, MD, Frederic Lemay, and Christian Iorio-Morin, M.D. Ph.D..Area of expertise
1Cancer
Stage IV
metastatic
2Breast Cancer
ER positive
HER2 negative
Stage IV
Top PIs
Paul Bessette, MDCHUS - Hôpital Fleurimont4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
8 reported clinical trials
12 drugs studied
Francois Lamontagne, MDCentre Hospitalier Universitaire de Sherbrooke4 years of reported clinical research
Studies COVID-19
Studies Coronavirus
7 reported clinical trials
76 drugs studied
Frederic LemayCentre Hospitalier Universitaire de Sherbrooke-Fleurimont4 years of reported clinical research
Studies Colorectal Cancer
Studies Pancreatic Adenocarcinoma
6 reported clinical trials
18 drugs studied
Christian Iorio-Morin, M.D. Ph.D.Centre Hospitalier Universitaire de Sherbrooke1 year of reported clinical research
Studies Hematoma
Studies Subdural Hematoma
4 reported clinical trials
7 drugs studied
Clinical Trials running at Centre Hospitalier Universitaire de Sherbrooke
Subdural Hematoma
Hematoma
Breast Cancer
Tracheostomy Complications
Crohn's Disease
Non-Epileptic Seizure Syndrome
Depression
Stereotypical and Intermittent Symptoms
Epilepsy
Seizures
Anticonvulsants
for Subdural Hematoma
This study is evaluating whether a drug called Topiramate might be more effective than another drug called Levetiracetam in treating patients with chronic subdural hematomas and transient neurological symptoms.
Recruiting5 awards Phase 44 criteria
Tranexamic Acid
for Subdural Hematoma
BACKGROUND Chronic subdural hematoma (CSDH) is one of the most frequent reasons for cranial neurosurgical consult. There is no widely accepted medical treatment for CSDH. This trial will investigate whether Tranexamic Acid (TXA) can increase the rate of CSDH resolution following conservative management, lower the number of required surgical procedures and decrease the rate of CSDH recurrence following surgical evacuation. TRACS is a double blind, randomized, parallel-design, placebo-controlled, phase IIB study designed to provide preliminary efficacy data as well as feasibility, safety and incidence data required to plan a larger definitive phase III trial. METHODS Consecutive patients presenting at the Centre Hospitalier Universitaire de Sherbrooke with a recent (< 14 days) diagnosis of subdural hematoma with a chronic component will be screened for eligibility. Exclusion criteria include specific risk factors for thromboembolic disease, anticoagulant use or contraindication to TXA. A total of 130 patients will be randomized to receive either 750 mg of TXA daily or placebo until complete radiological resolution of the CSDH or for a maximum of 20 weeks. CSDH volume will be measured on serial CT scanning. Cognitive function tests, quality of life questionnaires as well as functional autonomy assessments will be performed at enrollment, 10 weeks follow-up and 3 months post-treatment follow-up. During the treatment period, patients will undergo standard CSDH management with surgery being performed at the discretion of the treating physician. If surgery is performed, the CSDH and its outer membrane will be sampled for in vitro analysis. The primary outcome is the rate of CSDH resolution at 20 weeks without intervening unplanned surgical procedure. Secondary outcomes include CSDH volume, incidence of surgical evacuation procedures, CSDH recurrence, cognitive functions, functional autonomy, quality of life, incidence of complications and length of hospital stay. Planned subgroup analyses will be performed for conservatively vs surgically-managed subjects and highly vs poorly vascularised CSDH. DISCUSSION CSDH is a frequent and morbid condition for which an effective medical treatment has yet to be discovered. The TRACS trial will be the first prospective study of TXA for CSDH.
Recruiting0 awards Phase 2 & 32 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Centre Hospitalier Universitaire de Sherbrooke?
Centre Hospitalier Universitaire de Sherbrooke is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Cancer, Breast Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Obesity and other specialties. Centre Hospitalier Universitaire de Sherbrooke is involved with conducting 134 clinical trials across 249 conditions. There are 17 research doctors associated with this hospital, such as Paul Bessette, MD, Francois Lamontagne, MD, Frederic Lemay, and Christian Iorio-Morin, M.D. Ph.D..